4-(2-苯氧基乙基)吗啉 | 1209-10-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: 4-(2-苯氧基乙基)吗啉
• 英文名称: 4-(2-phenoxyethyl)morpholine
• 英文别名: 4-(2-phenoxy-ethyl)-morpholine；4-(2-Phenoxy-aethyl)-morpholin；N-(2-phenoxyethyl) morpholine；N-Morpholinoaethylphenylaether
• CAS: 1209-10-5
• 化学式: C₁₂H₁₇NO₂
• mdl: MFCD00454316
• 分子量: 207.272
• InChiKey: FDMDXNDAQKLGBA-UHFFFAOYSA-N

物化性质

• 沸点：
  323.1±27.0 °C(Predicted)
• 密度：
  1.065±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  21.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-苯氧基乙基)吗啉 在 氢氟酸 作用下， 以74%的产率得到Perfluoro<4-(2-cyclohexyloxyethyl)morpholine>
  参考文献：
  名称：

  On the electrochemical fluorination of aminoethers to give perfluoroaminoethers: possible candidates for blood substitutes

  摘要：

  Aminoethers, ROC2H4 activated NCH2CH2OCH2CH2 (R = C6H5, C6F5, C2H5), C6F5OC2H4N[CH2]5, were electrofluorinated in anhydrous hydrogen fluoride, the corresponding saturated perfluoroaminoethers being the largest individual substances in each case. One of them, F-[4-(2-cyclohexyloxyethyl)morpholine], has promising properties as a blood substitute.

  DOI：

  10.1016/s0022-1139(00)80346-2
• 作为产物：
  描述：

  N-(2-氯乙基)吗啉盐酸盐 、 苯酚 在 sodium hydroxide 作用下， 生成 4-(2-苯氧基乙基)吗啉
  参考文献：
  名称：

  Ethers and Amines from β-4-Morpholinoethyl Chloride

  摘要：

  DOI：

  10.1021/ja01863a033

文献信息

• Mustard Carbonate Analogues as Sustainable Reagents for the Aminoalkylation of Phenols
  作者：Mattia Annatelli、Giacomo Trapasso、Claudio Salaris、Cristiano Salata、Sabrina Castellano、Fabio Aricò

  DOI：10.1002/ejoc.202100328

  日期：2021.6.25

  The nitrogen mustard gas moiety is present as a basic, amine-containing side chain in numerous pharmacophore scaffolds engaging in crucial interactions with targeted biological macromolecules. Herein, a one-pot synthetic approach for the easy introduction of nitrogen mustard-like moieties through dialkyl carbonate chemistry into different phenolic substrates is reported. The scope and limitations of

  氮芥气部分作为碱性含胺侧链存在于许多与靶向生物大分子进行关键相互作用的药效团支架中。本文报道了一种通过碳酸二烷基酯化学将氮芥样部分轻松引入不同酚类底物的一锅合成方法。已经研究了该反应作为酚类 -OH 基团的无氯直接取代的范围和局限性。
• Pyrimidinone Derivatives as Antimalarial Agents
  申请人：SANOFI

  公开号：US20150183804A1

  公开（公告）日：2015-07-02

  The invention relates to novel pyrimidinone-based heterocyclic compounds which are parasite growth inhibitors, having the general formula (I) in which Y is a morpholine chosen from three bridged morpholines, L is a bond or a linker, n=0 or 1 and R 2 is a methyl group when n=0 and a hydrogen atom when n=1. Process for the preparation thereof and therapeutic use thereof.

  这项发明涉及一种新型的嘧啶酮基杂环化合物，这些化合物是寄生虫生长抑制剂，其一般式为（I），其中Y是从三种桥联吗啉中选择的吗啉，L是键或连接物，n=0或1，当n=0时R2是甲基基团，当n=1时是氢原子。其制备方法和治疗用途。
• Prodrugs of proton pump inhibitors
  申请人：Regents of the University of California

  公开号：US06559167B1

  公开（公告）日：2003-05-06

  Prodrugs of the pyridyl methyl sulfinyl benzimidazole type proton pump inhibitor drugs have a hydrolyzable arylsulfonyl or heteroarylsulfonyl group attached to the benzimidazole nitrogen. The prodrugs of the invention hydrolyze under physiological conditions to provide the proton pump inhibitors with a half life measurable in hours, and are capable of providing sustained plasma concentrations of the proton pump inhibitor drugs for longer time than presently used drugs. The generation of the proton pump inhibitor drugs from the prodrugs of the invention under physiological conditions allows for more effective treatment of several diseases and conditions caused by gastric acid secretion.

  该类型的吡啶甲基亚砜基苯并咪唑类质子泵抑制剂药物的前药，其将可水解的芳基磺酰基或杂环芳基磺酰基连接到咪唑类氮原子上。本发明的前药在生理条件下水解，提供半衰期可在小时内测量的质子泵抑制剂，并能够提供比目前使用的药物更长时间的持续血浆浓度。在生理条件下从本发明的前药生成质子泵抑制剂药物，可更有效地治疗由胃酸分泌引起的多种疾病和症状。
• [EN] BENZO[A]PHENAZIN-11-CARBOXAMIDE DERIVATIVES AND THEIR USE AS JOINT INHIBITORS OF TOPOMERASE I AND II<br/>[FR] DERIVES DE BENZO[A]PHENAZINE-11-CARBOXAMIDE ET LEUR UTILISATION COMME INHIBITEURS COMMUNS DE LA TOPOMERASE I ET II
  申请人：XENOVA LTD

  公开号：WO2001046157A1

  公开（公告）日：2001-06-28

  A compound which is a benzo[a]phenazine-11-carboxamide derivative of formula (I) wherein each of R1 to R4, which are the same or different, is selected from hydrogen, halogen, hydroxyl, C¿1?-C6 alkoxy which is unsubstituted or substituted, heteroaryloxy, C1-C6 alkyl which is unsubstituted or substituted, nitro, cyano, azido, amidoxime, CO2R?10, CON(R12)¿2, OCON(R?12), SR10, SOR11, SO¿2(R11), SO2N(R12)2, N(R12)2, NR10SO2R11, N(SO¿2R?11)2NR10(CH2)nCN, NR?10COR11, OCOR11 or COR10¿; each of R5 to R7, which are the same or different, is selected from hydrogen, halogen, hydroxy, C¿1?-C6 alkoxy, C1-C6 alkyl, SR?10¿ and N(R12)2; Q is C1-C6 alkylene which is unsubstituted or substituted by (i) C1-C6 alkyl which is unsubstituted or substituted, (ii) hydroxy, provided that the hydroxy group is not α to either of the N atoms adjacent to Q in formula (I), (iii) CO2R10, or (iv) CON(R?12); R8 and R9¿, which are the same or different, are each hydrogen or C¿1?-C6 alkyl, or R?8 and R9¿ together with the nitrogen atom to which they are attached form a saturated 5- or 6-membered N-containing heterocyclic ring which may include one additional heteroatom selected from O, N and S, or one of R?8 and R9¿ is an alkylene chain optionally interrupted by O, N or S, which is attached to a carbon atom on the alkylene chain represented by Q to complete a saturated 5- or 6-membered N-containing heterocyclic ring as defined above; or a pharmaceutically acceptable salt thereof; with the proviso that at least one R1 to R4 is other than hydrogen. These compounds are inhibitors of topoisomerase I and/or topoisomerase II and can be used to treat tumours, including tumours which express MDR.

  化合物是公式（I）的苯并[a]菲噻唑-11-羧酰胺衍生物，其中R1至R4中的每一个，相同或不同，从氢，卤素，羟基，未取代或取代的C1-C6烷氧基，杂环氧基，未取代或取代的C1-C6烷基，硝基，氰基，偶氮基，酰肟基，CO2R10，CON（R12）2，OCON（R12），SR10，SOR11，SO2（R11），SO2N（R12）2，N（R12）2，NR10SO2R11，N（SO2R11）2NR10（CH2）nCN，NR10COR11，OCOR11或COR10中选择；R5至R7中的每一个，相同或不同，从氢，卤素，羟基，C1-C6烷氧基，C1-C6烷基，SR10和N（R12）2中选择；Q是未取代或取代的C1-C6烷基，由（i）未取代或取代的C1-C6烷基，（ii）羟基，前提是羟基不是在公式（I）中与Q相邻的任何一个氮原子的α位上，（iii）CO2R10或（iv）CON（R12）取代的；R8和R9'，相同或不同，均为氢或C1-C6烷基，或R8和R9'与它们连接的氮原子共同形成饱和的5-或6-成员N-含杂环，该杂环可以包括从O，N和S中选择的一个额外的杂原子，或R8和R9'中的一个是由O，N或S间断的烷基链，该烷基链连接到由Q表示的烷基链上的碳原子以形成上述定义的饱和的5-或6-成员N-含杂环；或其药学上可接受的盐；但至少有一个R1至R4不是氢。这些化合物是拓扑异构酶I和/或拓扑异构酶II的抑制剂，可用于治疗肿瘤，包括表达MDR的肿瘤。
• METHODS FOR TREATING HEPATITIS C
  申请人：Karp Gary M.

  公开号：US20100292187A1

  公开（公告）日：2010-11-18

  The present invention provides compounds, pharmaceutical compositions, and methods of using such compounds or compositions for treating infection by a virus, or for affecting viral IRES activity.

  本发明提供了化合物、药物组合物以及使用这些化合物或组合物治疗病毒感染或影响病毒IRES活性的方法。